See more : Alfresa Holdings Corporation (ALFRY) Income Statement Analysis – Financial Results
Complete financial analysis of Mirum Pharmaceuticals, Inc. (MIRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mirum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Enerside Energy, S.A. (ENRS.MC) Income Statement Analysis – Financial Results
- Juma Technology Corp. (JUMT) Income Statement Analysis – Financial Results
- High Performance Beverages Company (TBEV) Income Statement Analysis – Financial Results
- Europlasma SA (1EZ0.MU) Income Statement Analysis – Financial Results
- Zhongrui shares (301587.SZ) Income Statement Analysis – Financial Results
Mirum Pharmaceuticals, Inc. (MIRM)
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 186.37M | 77.06M | 19.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 47.04M | 12.37M | 1.90M | 623.00K | 324.00K | 0.00 |
| Gross Profit | 139.34M | 64.69M | 17.24M | -623.00K | -324.00K | 0.00 |
| Gross Profit Ratio | 74.76% | 83.94% | 90.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M | 2.33M |
| General & Administrative | 139.58M | 16.96M | 59.22M | 22.69M | 11.75M | 877.50K |
| Selling & Marketing | 6.30M | 72.11M | 9.20M | 0.00 | 0.00 | -292.50K |
| SG&A | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M | 585.00K |
| Other Expenses | 0.00 | 365.00K | 107.42M | -192.00K | -21.00K | 0.00 |
| Operating Expenses | 248.49M | 195.91M | 190.65M | 104.30M | 54.74M | 2.92M |
| Cost & Expenses | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M | 2.92M |
| Interest Income | 13.74M | 3.86M | 366.00K | 1.56M | 2.23M | 87.00K |
| Interest Expense | 15.11M | 15.98M | 17.59M | 335.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 10.83M | 3.68M | 975.00K | 623.00K | 324.00K | 4.37M |
| EBITDA | -136.49M | -122.41M | -65.39M | -102.31M | -52.21M | -17.33M |
| EBITDA Ratio | -73.23% | -164.80% | -337.83% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M | -2.92M |
| Operating Income Ratio | -58.57% | -170.28% | -906.12% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -53.27M | -10.85M | 89.46M | 1.03M | 2.21M | -14.43M |
| Income Before Tax | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
| Income Before Tax Ratio | -87.15% | -184.36% | -438.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K | -4.37M |
| Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M | -17.35M |
| Net Income Ratio | -87.68% | -176.05% | -438.85% | 0.00% | 0.00% | 0.00% |
| EPS | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS Diluted | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Weighted Avg Shares Out | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
| Weighted Avg Shares Out (Dil) | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #liverdisease--Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum: Must Watch Biotech On Release Of Results From EMBARK Study
Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with biliary atresia, are expected in the 2nd half of 2023. It is expected that the global Biliary Atresia market could grow to $1.69...
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress.
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President & Chief Executive Officer Peter Radovich - Chief Operating...
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.17 per share a year ago.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer...
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings Season
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Source: https://incomestatements.info
Category: Stock Reports